BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Labandeira CM, Fraga-Bau A, Arias Ron D, Muñoz A, Alonso-Losada G, Koukoulis A, Romero-Lopez J, Rodriguez-Perez AI. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists. Front Neuroendocrinol 2021;62:100914. [PMID: 33845041 DOI: 10.1016/j.yfrne.2021.100914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Pedrosa MA, Labandeira CM, Valenzuela R, Quijano A, Sanchez-Andrade M, Suarez-Quintanilla JA, Lanciego JL, Labandeira-Garcia JL, Rodriguez-Perez AI. AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability. Brain Behav Immun 2023;108:255-68. [PMID: 36535607 DOI: 10.1016/j.bbi.2022.12.009] [Reference Citation Analysis]
2 Park KW, Hwang YS, Lee SH, Jo S, Chung SJ. The Effect of Blood Lipids, Type 2 Diabetes, and Body Mass Index on Parkinson's Disease: A Korean Mendelian Randomization Study. J Mov Disord 2023;16:79-85. [PMID: 36628424 DOI: 10.14802/jmd.22175] [Reference Citation Analysis]
3 Shen Z, Yu M, Zhang S, Surguchov A. Network Pharmacology and Molecular Docking Analyses Unveil the Mechanisms of Yiguanjian Decoction against Parkinson’s Disease from Inner/Outer Brain Perspective. BioMed Research International 2022;2022:1-25. [DOI: 10.1155/2022/4758189] [Reference Citation Analysis]
4 Luo A, Xie Z, Wang Y, Wang X, Li S, Yan J, Zhan G, Zhou Z, Zhao Y, Li S. Type 2 diabetes mellitus-associated cognitive dysfunction: Advances in potential mechanisms and therapies. Neurosci Biobehav Rev 2022;137:104642. [PMID: 35367221 DOI: 10.1016/j.neubiorev.2022.104642] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Chmiela T, Węgrzynek J, Kasprzyk A, Waksmundzki D, Wilczek D, Gorzkowska A. If Not Insulin Resistance so What? - Comparison of Fasting Glycemia in Idiopathic Parkinson's Disease and Atypical Parkinsonism. Diabetes Metab Syndr Obes 2022;15:1451-60. [PMID: 35586204 DOI: 10.2147/DMSO.S359856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Capucho AM, Chegão A, Martins FO, Vicente Miranda H, Conde SV. Dysmetabolism and Neurodegeneration: Trick or Treat? Nutrients 2022;14:1425. [DOI: 10.3390/nu14071425] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Arbo BD, Schimith LE, Goulart dos Santos M, Hort MA. Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation. European Journal of Pharmacology 2022. [DOI: 10.1016/j.ejphar.2022.174800] [Reference Citation Analysis]
8 Wu W, Zhang X, Zhou J, Yang H, Chen J, Zhao L, Zhong J, Lin WJ, Wang Z. Clemastine Ameliorates Perioperative Neurocognitive Disorder in Aged Mice Caused by Anesthesia and Surgery. Front Pharmacol 2021;12:738590. [PMID: 34497527 DOI: 10.3389/fphar.2021.738590] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]